Natera (NTRA) Stock Price, News & Analysis

Company Overview

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection. Founded in 2004, Natera serves healthcare providers and patients in the United States and internationally. Steve Chapman is the company’s chief executive officer.

Key Stats

• Today's Range: $307.08 to $323.73
• 50-Day Range: $310.67 to $436.00
• 52-Week Range: $181.00 to $437.41
• Volume: 428,199 shs
• Average Volume: 1.46 million shs
• Market Capitalization: $45.55 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $394.31
• Consensus Rating: Moderate Buy

Natera Stock Analysis - MarketRank™

Natera scored higher than 82% of companies evaluated by MarketBeat, and ranked 78th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Natera has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 17 buy ratings, 2 hold ratings, and 2 sell ratings.

Upside Potential

Natera has a consensus price target of $394.31, representing about 23.1% upside from its current price of $320.39.

Amount of Analyst Coverage

Natera has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Natera are expected to grow in the coming year, from ($1.14) to ($0.10) per share.

Price to Book Value per Share Ratio

Natera has a P/B Ratio of 25.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.28% of the float of Natera has been sold short.

Short Interest Ratio / Days to Cover

Natera has a short interest ratio ("days to cover") of 3.43, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Natera has recently decreased by 7.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Natera does not currently pay a dividend.

Dividend Growth

Natera does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.27

News Sentiment

Natera has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 42 news articles for Natera this week, compared to 10 articles on an average week.

Search Interest

Only 12 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.

MarketBeat Follows

11 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,856,400.00 in company stock.

Percentage Held by Insiders

5.05% of the stock of Natera is held by insiders.

Percentage Held by Institutions

99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/10/2026
• 8th Annual Wolfe Research Healthcare Conference: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NTRA
• CIK: 1604821
• Web: www.natera.com
• Phone: (650) 249-9090
• Fax: N/A
• Employees: 6,140
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Natera: $394.31
• High Price Target: $500.00
• Low Price Target: $245.00
• Potential Upside/Downside: +24.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$208.16 million
• Net Margins: -7.11%
• Pretax Margin: -9.33%
• Return on Equity: -11.38%
• Return on Assets: -7.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.00
• Quick Ratio: 2.85

Sales & Book Value

• Annual Sales: $2.31 billion
• Price / Sales: 19.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.38 per share
• Price / Book: 25.59

Miscellaneous

• Outstanding Shares: 144,140,000
• Free Float: 136,865,000
• Market Cap: $45.67 billion
• Optionable: Optionable
• Beta: 1.55